Novartis AG - Company Snapshot & SWOT Analysis

Publication ID:

NAV0319003

Publication Date:

March 05, 2019

Pages:

Countries:

Global [1]

As per NAVADHI Market Research, the global pharmaceutical industry [2] will we worth USD 1.57 trillion by 2023.

Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales (50.13 billion US$) among the world-wide industry in 2017. On July 10 2015, Novartis became the largest Healthcare company by market capitalization, during intra-day trading, with a market-cap of $279.8 billion in comparison to Johnson & Johnson at $276.3 billion.

Novartis 2018 Revenue Performance at a glance

Novartis AG reported revenue of USD 51.90 billion for the FY 2018 which saw an increase of 5.68% compared to FY 2017. Novartis also announced that the spin-off of Alcon is still on-track, with the company awaiting the final endorsement of the move within the first half of the year.According to company statement , "Alcon is positioned for sustainable long-term top-line growth and margin expansion as demonstrated by the strong 2018 results,” Alcon division's total sale in 2018 was USD 7.14 Billion.

Spanning over 29 pages and 17 exhibits, “Novartis AG - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.

Scope of the Novartis AG- Company Snapshot & SWOT Analysis Report

This report provides detailed information about Novartis AG, Inc. including value chain analysis, financial performance, business strategy and SWOT analysis.
The report identifies the growth drivers and inhibitors for global pharmaceutical market.
This report provides information about current and future trends for global pharmaceutical market.

1. Executive Summary

Scope of the Novartis AG- Company Snapshot & SWOT Analysis Report

Research Methodology

2. Growth Drivers and Inhibitors for Global Pharmaceuticals Market

3. Company Profile

3.1 Novartis AG

3.1.1 Company Profile

3.2.2 Novartis AG in Global Pharmaceuticals Manufacturing Value Chain

3.2.3 Novartis AG: Financial Performance

3.2.3.1 Novartis AG: Overall Revenue FY 2013-FY 2019 (in USD billion)

3.2.3.2 Novartis AG: Geography-Wise Revenue FY 2018 (in USD billion)

3.2.3.3 Novartis AG: Therapy Area-Wise Revenue FY 2018 (in USD billion)

3.2.4 Novartis AG: Business Strategy

3.2.5 SWOT Analysis of Novartis AG

Strengths

Weaknesses

Opportunities

Threats

4. Current and Future Trends in Pharmaceutical Market

List of Exhibits

Notes

List of Exhibits

Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market

Exhibit 3.1 Key Information of Novartis AG

Exhibit 3.2 Contact Information of Novartis AG

Exhibit 3.3 Novartis AG in Pharmaceuticals Manufacturing Value Chain

Exhibit 3.4 Revenue of Novartis AG FY 2013- FY 2019 (in USD billion)

Exhibit 3.5 Revenue Growth of Novartis AG FY 2014- FY 2019 (in %)

Exhibit 3.6 Geography-Wise Revenue of Novartis AG in FY 2018 (in USD billion)

Exhibit 3.7 Therapy and Geography Area-Wise Revenue of Pfizer Inc. FY 2018 (in USD million)

Exhibit 3.8 Business Division-Wise Revenue of Novartis AG in FY 2018 (in USD million)

Exhibit 3.9 Pharmaceutical Segment Revenue of Novartis AG in FY 2018 (in USD million)

Exhibit 3.10 Innovative Medicines Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)

Exhibit 3.11 Sandoz Division Revenue of Novartis AG in FY 2018 (in USD million)

Exhibit 3.12 Sandoz Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)

Exhibit 3.13 Alcon Division Revenue of Novartis AG in FY 2018 (in USD million)

Exhibit 3.14 Alcon Division Revenue of Novartis AG FY 2017- FY 2019 (in USD billion)

Exhibit 3.15 10+ potential blockbuster launches planned by Novartis AG in the next 2 years

Exhibit 3.16 SWOT Analysis of Novartis AG

Novartis AG

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.